Abstract library

867 results for "clinical manifestations".
#928 Clinical Analysis of 245 Patients with GEP-NETs: A Single-Institution Analysis (2002–2013) in South China
Introduction: GEP-NETs are the most common types of NET, accounting for about 67.5% of total NET. But so far, there have been no related statistics of Chinese patients with GEP-NET. Here, we performed a retrospective study in South China to provide clinical characteristics of GEP-NET.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Ye Chen
Authors: Mo Z H, Chen Y
#428 Clinical Manifestations of Patients with Pancreatic ß Cells Hyperplasia
Introduction: Pathologic hyperplasia of pancreatic endocrine cells is uncommon. ß cell hyperplasia contributes to persistent hyperinsulinemic hypoglycemia. The manifestations of patients with pancreatic ß cells hyperplasia are variable and their preop. diagnosis is difficult.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Tsann Long Hwang
#1398 Surgical Management of Nonfunctioning Pancreatic Neuroendocrine Tumors 2 cm or Less in Size: Results from a Multi-institutional Clinical Analysis in China
Introduction: There is a paucity of evidence regarding surgical management and survival in nonfunctioning PNETs 2cm or less.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: Meng Ji
Authors: Ji M, Jin K, Zhang Y
#1649 Clinicopathological Features and Survival Analysis of 98 Patients with Gastroenteropancreatic Neuroendocrine Neoplasms
Introduction: To investigate the clinicopathological features and prognostic factors of 98 patients with gastrointestinal Pancreatic neuroendocrine tumors.
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: Xushan Tang
Authors: Tang X, Tang Y, She L
#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...
#157 Multiple Endocrine Neoplasia Type 1 (MEN-1), Hadassah-Hebrew University Medical Center experience
Introduction: MEN 1 is an autosomal dominant genetic disorder with a prevalence of 2-4 per 100,000. The main manifestations are parathyroid (PT), gastroenteropancreatic (GEP) and pituitary tumors, but may affect other organ systems as well. MEN 1 is associated with significant morbidity and mortality, with up to 50% dying before the age of 50. Treating MEN 1 patients presents a unique diagnostic and therapeutic challenge.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem
Authors: Kassem S, Glaser B, Barak D, Fraenkel M, ...
#1215 Describing NENs: Just Clinical/Biologic Features or Actual Prognostic Factors?
Introduction: Neuroendocrine neoplasias (NENs) are a rare group of diseases, with several possible locations and manifestations, often representing a challenging diagnosis. It is essential to improve tools that accurately predict aggressiveness and prognosis.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MSc Catarina Ribeiro
Authors: Ribeiro C, Gomes F, Semedo M, Filipe F, ...
#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?
Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
Keywords: Screening, MEN1
#136 Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors
Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg
#548 Hypoglycemic Syndrome in 30 Patients
Introduction:
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Irina Komerdus